Nona Biosciences Licenses H2L2 Harbour Mice Platform to UAB for B Cell Research
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...
HKG: 2142
Harbour BioMed Receives NMPA Clearance for COPD Treatment HBM9378/SKB378
China-based biopharmaceutical company Harbour BioMed (HKG: 2142) has announced receiving clinical clearance from China’s National...
Nona Biosciences Partners with Invetx for Animal Health Therapies
Nona Biosciences (HKG: 2142), a wholly-owned subsidiary of HBM Holdings Ltd, has announced a partnership...
Harbour BioMed and Kelun Biotech License TSLP Monoclonal Antibody to Windward Bio
Chinese firms Harbour BioMed (HKG: 2142) and Sichuan Kelun Biotech BioPharmaceutical (HKG: 6990) have entered...
Nona Biosciences Partners with Kodiak Sciences to Discover Multi-Target Ophthalmic Antibodies
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has joined forces with...
Harbour BioMed’s Innovative Antibody Porustobart Shows Promise in Early Clinical Trials for Melanoma
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
Nona Biosciences Partners with OverT Bio to Develop Next-Generation Cell Therapies for Solid Tumors
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...
Nona Biosciences Partners with Alkyon Therapeutics to Develop Next-Generation Immunotherapies
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...
Harbour BioMed’s 2024 H1 Revenues Decline Amid R&D Optimization and Pipeline Advancements
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
Nona Biosciences and Umoja Biopharma Join Forces to Develop In Vivo CAR-T Therapies
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...
Nona Biosciences Partners with Alaya.bio to Revolutionize CAR-T Therapy Development
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...
Harbour BioMed Resubmits Biological License Application for Batoclimab in China
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
AstraZeneca Partners with Nona Biosciences in Multimillion-Dollar Monoclonal Antibody Agreement
HBM Holdings Ltd’s (HKG: 2142) wholly-owned subsidiary, Nona Biosciences, has announced a significant licensing agreement...
Harbour BioMed Reports Triple-Digit Revenue Growth and First-Ever Net Profit in 2023 Financial Results
Harbour BioMed (HKG: 2142), a biopharmaceutical company with a global presence in Suzhou, China, Cambridge...
Harbour BioMed Partners with Boostimmune to Develop Novel ADC Therapies
Harbour BioMed (HKG: 2142), a biotechnology company with operations in Suzhou, China, Cambridge in the...
Harbour BioMed Gets FDA Green Light for Phase I Study of BsAb Targeting PD-L1 and CD40
Harbour BioMed (HKG: 2142), a biotechnology company with operations in Suzhou, China, Cambridge in the...
Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer
Dr. Chris Boshoff, Pfizer (NYSE: PFE)’s recently appointed chief oncology officer, disclosed in an interview...
Seagen Inc. Acquires Global Rights to HBM9033 ADC in Deal with Nona Biosciences and Medilink Therapeutics
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), and Suzhou-based Medilink Therapeutics have...
Nona Biosciences Partners with Evive Biotech to Discover H2L2 Antibodies Using Harbour Mice Platform
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...
Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has announced a collaboration...